NCT03111381View on ClinicalTrials.gov

Toradol to Reduce Ureteroscopic Symptoms Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

June 1, 2020

Study Completion Date

June 1, 2020

Conditions
Urinary LithiasisKidney DiseasesKidney StonePain, Postoperative
Interventions
DRUG

Toradol

IV toradol

Trial Locations (1)

06520

Yale Medial Center, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT03111381 - Toradol to Reduce Ureteroscopic Symptoms Trial | Biotech Hunter | Biotech Hunter